<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00628706</url>
  </required_header>
  <id_info>
    <org_study_id>THC-phMRI-01</org_study_id>
    <nct_id>NCT00628706</nct_id>
  </id_info>
  <brief_title>Investigating the Acute Effects of THC on Functional Brain Systems</brief_title>
  <acronym>FIX</acronym>
  <official_title>Investigating the Acute Effects of THC on Functional Brain Systems</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Center for Human Drug Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>TI Pharma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether THC, the main psychoactive ingredient in
      cannabis, affects functional brain systems underlying memory and reward.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cannabis is by far the most frequently used illicit drug worldwide and has significant
      effects on memory. Further, cannabis has an addictive potential. These effects are mediated
      by an action of THC, the main psychoactive ingredient of cannabis, on cannabinoid CB1
      receptors. These receptors are particularly highly expressed in brain regions involved in
      memory and reward. Therefore, in this study we will investigate the acute effects of THC on
      functional brain systems underlying memory and reward. We will visualize these effects using
      the latest non-invasive imaging technique: pharmacological MRI (phMRI).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The main study parameter is the blood oxygen level dependent (BOLD) signal.</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Behavioral parameters (two VAS questionnaires)</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral blood flow (ASL)</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of plasma THC and its main metabolites</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on neuropsychological tests</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Reward</condition>
  <condition>Tetrahydrocannabinol</condition>
  <condition>Endocannabinoids</condition>
  <condition>Memory</condition>
  <condition>Magnetic Resonance Imaging</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhalation of THC, using a Volcano vaporizer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhalation of vehicle, using a Volcano vaporizer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delta9-tetrahydrocannabinol (THC)</intervention_name>
    <description>inhalation of 6 mg liquid THC, vaporized by means of a Volcano vaporizer</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>dronabinol, marinol, THC, tetrahydrocannabinol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of mild cannabis use for at least one year (&lt;1/week and â‰¥ 4/year)

          -  History without psychotic experiences after cannabis use

          -  Age between 18 and 45 years

          -  Right-handedness, assessed with the Edinburgh Handedness Inventory

          -  Written informed consent of the subject

        Exclusion Criteria:

          -  Any clinical significant abnormality of any clinical laboratory test, including
             urinary drug screening

          -  Impaired physical health evaluated by medical history, physical (including
             neurological) examination and screening laboratory tests

          -  History of clinically significant psychiatric or neurological illness

          -  History of clinically significant psychiatric or neurological illness in first- or
             second-degree relatives

          -  History of alcohol and/or drug abuse (DSM-IV criteria)

          -  Body Mass Index (B.M.I.) &lt;18 kg/m2 or &gt;28 kg/m2

          -  Paranoid ideation or psychoticism on SCL-90

          -  Any subject who received any investigational medication within 90 days prior to the
             start of the study or who is scheduled to receive an investigational drug

          -  The use of any medication within three weeks prior to the start of the study, except
             for paracetamol

          -  Positive HIV or Hepatitis B/C test

          -  Blood donation within 3 months before the start of the study

          -  Claustrophobia

          -  Metal objects in or around the body (braces, pacemaker, metal fragments)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nick Ramsey, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2008</study_first_submitted>
  <study_first_submitted_qc>February 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2008</study_first_posted>
  <last_update_submitted>February 17, 2009</last_update_submitted>
  <last_update_submitted_qc>February 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof. N.F. Ramsey</name_title>
    <organization>UMC Utrecht</organization>
  </responsible_party>
  <keyword>tetrahydrocannabinol</keyword>
  <keyword>memory</keyword>
  <keyword>reward</keyword>
  <keyword>magnetic resonance imaging</keyword>
  <keyword>endocannabinoids</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

